marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-31-2024
Alnylam Pharmaceuticals Balance Sheet 2011-2024 | ALNY
Annual Balance Sheet Alnylam Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
250 M | 193 M | -498 M | -268 M | -243 M | -390 M | -615 M | -43.6 M | -181 M | -75.2 M | -53.2 M | -51.4 M | -70.2 M |
Long Term Debt |
1.02 B | 1.02 B | 281 M | 191 M | - | 30 M | 30 M | 150 M | - | - | - | - | - |
Long Term Debt Current |
41.5 M | 42 M | 40.5 M | 36.9 M | 27.7 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 604 M | 93.3 M | 84 M | 211 M | 59.7 M | 48 M | 96.3 M | 105 M | 82.9 M |
Total Current Liabilities |
968 M | 768 M | 696 M | 585 M | 353 M | 179 M | 144 M | 132 M | 62.1 M | 95.3 M | 53.9 M | 48.3 M | 81 M |
Total Liabilities |
4.05 B | 3.7 B | 3.06 B | 2.39 B | 956 M | 273 M | 228 M | 343 M | 122 M | 143 M | 150 M | 153 M | 164 M |
Deferred Revenue |
103 M | 42.1 M | 149 M | 127 M | 77.8 M | 3.5 M | 41.7 M | 33.5 M | 15.4 M | 23.9 M | 32.7 M | 31.4 M | 62.4 M |
Retained Earnings |
-7.01 B | -6.57 B | -5.44 B | -4.59 B | -3.73 B | -2.84 B | -2.15 B | -1.66 B | -1.25 B | -957 M | -596 M | -507 M | -401 M |
Total Assets |
3.83 B | 3.55 B | 3.64 B | 3.41 B | 2.4 B | 1.57 B | 1.99 B | 1.26 B | 1.39 B | 1.08 B | 421 M | 288 M | 282 M |
Cash and Cash Equivalents |
813 M | 866 M | 820 M | 497 M | 547 M | 420 M | 645 M | 194 M | 181 M | 75.2 M | 53.2 M | 51.4 M | 70.2 M |
Book Value |
-221 M | -158 M | 588 M | 1.02 B | 1.44 B | 1.3 B | 1.77 B | 920 M | 1.26 B | 936 M | 270 M | 134 M | 118 M |
Total Shareholders Equity |
-221 M | -158 M | 588 M | 1.02 B | 1.44 B | 1.3 B | 1.77 B | 920 M | 1.26 B | 936 M | 270 M | 134 M | 118 M |
All numbers in USD currency
Quarterly Balance Sheet Alnylam Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | - | 677 M | 676 M | 434 M | 433 M | 192 M | 191 M | 293 M | 191 M | 191 M | 276 M | 276 M | 276 M | 276 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.17 B | 4.01 B | 4.04 B | 4.05 B | 4 B | 3.81 B | 3.65 B | 3.7 B | 3.6 B | - | 3.03 B | 3.06 B | 2.72 B | 2.66 B | 2.33 B | 2.39 B | 2.39 B | 2.39 B | 2.39 B | 956 M | 956 M | 956 M | 956 M | 273 M | 273 M | 273 M | 273 M | 228 M | 228 M | 228 M | 228 M | 343 M | 343 M | 343 M | 343 M | 122 M | 122 M | 122 M | 122 M | 143 M | 143 M | 143 M | 143 M | 150 M | 150 M | 150 M | 150 M | 153 M | 153 M | 153 M | 153 M | 164 M | 164 M | 164 M | 164 M |
Deferred Revenue |
71 M | 69 M | 76.8 M | 103 M | 77.1 M | 54.6 M | 35.8 M | 42.1 M | 144 M | - | 132 M | 149 M | 115 M | 98.1 M | 116 M | 127 M | 127 M | 127 M | 127 M | 77.8 M | 77.8 M | 77.8 M | 77.8 M | 3.5 M | 3.5 M | 3.5 M | 35.9 M | 41.7 M | 38.5 M | 39.8 M | 36.8 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 23.9 M | 23.9 M | 23.9 M | 23.9 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 62.4 M | 62.4 M | 62.4 M | 62.4 M |
Retained Earnings |
-7.2 B | -7.09 B | -7.08 B | -7.01 B | -6.87 B | -7.02 B | -6.74 B | -6.57 B | -6.36 B | - | -5.68 B | -5.44 B | -5.18 B | -4.98 B | -4.79 B | -4.59 B | -4.59 B | -4.59 B | -4.59 B | -3.73 B | -3.73 B | -3.73 B | -3.73 B | -2.84 B | -2.84 B | -2.84 B | -2.84 B | -2.15 B | -2.15 B | -2.15 B | -2.15 B | -1.66 B | -1.66 B | -1.66 B | -1.66 B | -1.25 B | -1.25 B | -1.25 B | -1.25 B | -957 M | -957 M | -957 M | -957 M | -596 M | -596 M | -596 M | -596 M | -507 M | -507 M | -507 M | -507 M | -401 M | -401 M | -401 M | -401 M |
Total Assets |
4.21 B | 4.01 B | 3.82 B | 3.83 B | 3.84 B | 3.4 B | 3.39 B | 3.55 B | 3.54 B | - | 3.43 B | 3.64 B | 3.47 B | 3.51 B | 3.26 B | 3.41 B | 3.41 B | 3.41 B | 3.41 B | 2.4 B | 2.4 B | 2.4 B | 2.4 B | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 1.99 B | 1.99 B | 1.99 B | 1.99 B | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 1.39 B | 1.39 B | 1.39 B | 1.39 B | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 421 M | 421 M | 421 M | 421 M | 288 M | 288 M | 288 M | 288 M | 282 M | 282 M | 282 M | 282 M |
Cash and Cash Equivalents |
1.1 B | 968 M | 682 M | 813 M | 1.03 B | 658 M | 672 M | 866 M | 1.07 B | 576 M | 534 M | 820 M | 1.09 B | 746 M | 380 M | 497 M | 497 M | 497 M | 497 M | 547 M | 547 M | 547 M | 547 M | 420 M | 420 M | 420 M | 420 M | 645 M | 645 M | 645 M | 645 M | 194 M | 194 M | 194 M | 194 M | 181 M | 181 M | 181 M | 181 M | 75.2 M | 75.2 M | 75.2 M | 75.2 M | 53.2 M | 53.2 M | 53.2 M | 53.2 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 70.2 M | 70.2 M | 70.2 M | 70.2 M |
Book Value |
32.4 M | -3.07 M | -219 M | -221 M | -166 M | -408 M | -259 M | -158 M | -67.6 M | - | 401 M | 588 M | 756 M | 853 M | 926 M | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.44 B | 1.44 B | 1.44 B | 1.44 B | 1.3 B | 1.3 B | 1.3 B | 1.3 B | 1.77 B | 1.77 B | 1.77 B | 1.77 B | 920 M | 920 M | 920 M | 920 M | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 936 M | 936 M | 936 M | 936 M | 270 M | 270 M | 270 M | 270 M | 134 M | 134 M | 134 M | 134 M | 118 M | 118 M | 118 M | 118 M |
Total Shareholders Equity |
32.4 M | -3.07 M | -219 M | -221 M | -166 M | -408 M | -259 M | -158 M | -67.6 M | 176 M | 401 M | 588 M | 756 M | 853 M | 926 M | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 1.44 B | 1.44 B | 1.44 B | 1.44 B | 1.3 B | 1.3 B | 1.3 B | 1.3 B | 1.77 B | 1.77 B | 1.77 B | 1.77 B | 920 M | 920 M | 920 M | 920 M | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 936 M | 936 M | 936 M | 936 M | 270 M | 270 M | 270 M | 270 M | 134 M | 134 M | 134 M | 134 M | 118 M | 118 M | 118 M | 118 M |
All numbers in USD currency